Tags

Type your tag names separated by a space and hit enter

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects.

Abstract

BACKGROUND

Interactions between glutamatergic and endocannabinoid systems may contribute to schizophrenia, dissociative states, and other psychiatric conditions. Cannabidiol (CBD), a cannabinoid-1/2 (CB1/2) receptor weak partial agonist or antagonist, may play a role in the treatment of schizophrenia.

OBJECTIVE

This study tested the hypothesis that CBD would attenuate the behavioral effects of the NMDA receptor antagonist, ketamine, in healthy human subjects.

METHODS

Ten male healthy volunteers were evaluated twice in a randomized order. In both sessions they received ketamine (bolus of 0.26 mg/kg/1 min followed by IV infusion of 0.25mg/kg over 30 min) preceded by either CBD (600 mg) or placebo. Psychopathology was assessed using the Brief Psychiatric Rating Scale (BPRS) and the CADSS (Clinician Administered Dissociative States Scale) at regular intervals from 30 min before to 90 min after ketamine administration.

RESULTS

CBD significantly augmented the activating effects of ketamine, as measured by the activation subscales of the BPRS. However, CBD also showed a non-significant trend to reduce ketamine-induced depersonalization, as measured by the CADSS.

CONCLUSION

These data describe a complex pattern of psychopharmacologic interactions between CBD and ketamine at the doses of each agent studied in this experiment.

Authors+Show Affiliations

Department of Neuroscience and Behavior, University of São Paulo, Ribeirão Preto, Brazil. jhallak@fmrp.usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

21062637

Citation

Hallak, Jaime E C., et al. "The Interplay of Cannabinoid and NMDA Glutamate Receptor Systems in Humans: Preliminary Evidence of Interactive Effects of Cannabidiol and Ketamine in Healthy Human Subjects." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 35, no. 1, 2011, pp. 198-202.
Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):198-202.
Hallak, J. E., Dursun, S. M., Bosi, D. C., de Macedo, L. R., Machado-de-Sousa, J. P., Abrão, J., ... Zuardi, A. W. (2011). The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Progress in Neuro-psychopharmacology & Biological Psychiatry, 35(1), pp. 198-202. doi:10.1016/j.pnpbp.2010.11.002.
Hallak JE, et al. The Interplay of Cannabinoid and NMDA Glutamate Receptor Systems in Humans: Preliminary Evidence of Interactive Effects of Cannabidiol and Ketamine in Healthy Human Subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):198-202. PubMed PMID: 21062637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. AU - Hallak,Jaime E C, AU - Dursun,Serdar M, AU - Bosi,Daniel C, AU - de Macedo,Ligia Ribeiro Horta, AU - Machado-de-Sousa,João Paulo, AU - Abrão,João, AU - Crippa,José A S, AU - McGuire,Phillip, AU - Krystal,John H, AU - Baker,Glen B, AU - Zuardi,Antonio W, Y1 - 2010/11/07/ PY - 2010/06/01/received PY - 2010/11/01/revised PY - 2010/11/01/accepted PY - 2010/11/11/entrez PY - 2010/11/11/pubmed PY - 2011/5/4/medline SP - 198 EP - 202 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 35 IS - 1 N2 - BACKGROUND: Interactions between glutamatergic and endocannabinoid systems may contribute to schizophrenia, dissociative states, and other psychiatric conditions. Cannabidiol (CBD), a cannabinoid-1/2 (CB1/2) receptor weak partial agonist or antagonist, may play a role in the treatment of schizophrenia. OBJECTIVE: This study tested the hypothesis that CBD would attenuate the behavioral effects of the NMDA receptor antagonist, ketamine, in healthy human subjects. METHODS: Ten male healthy volunteers were evaluated twice in a randomized order. In both sessions they received ketamine (bolus of 0.26 mg/kg/1 min followed by IV infusion of 0.25mg/kg over 30 min) preceded by either CBD (600 mg) or placebo. Psychopathology was assessed using the Brief Psychiatric Rating Scale (BPRS) and the CADSS (Clinician Administered Dissociative States Scale) at regular intervals from 30 min before to 90 min after ketamine administration. RESULTS: CBD significantly augmented the activating effects of ketamine, as measured by the activation subscales of the BPRS. However, CBD also showed a non-significant trend to reduce ketamine-induced depersonalization, as measured by the CADSS. CONCLUSION: These data describe a complex pattern of psychopharmacologic interactions between CBD and ketamine at the doses of each agent studied in this experiment. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/21062637/abstract/The_interplay_of_cannabinoid_and_NMDA_glutamate_receptor_systems_in_humans:_preliminary_evidence_of_interactive_effects_of_cannabidiol_and_ketamine_in_healthy_human_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(10)00416-1 DB - PRIME DP - Unbound Medicine ER -